ES2190484T3 - Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano. - Google Patents

Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano.

Info

Publication number
ES2190484T3
ES2190484T3 ES96942362T ES96942362T ES2190484T3 ES 2190484 T3 ES2190484 T3 ES 2190484T3 ES 96942362 T ES96942362 T ES 96942362T ES 96942362 T ES96942362 T ES 96942362T ES 2190484 T3 ES2190484 T3 ES 2190484T3
Authority
ES
Spain
Prior art keywords
diagnosis
procedure
plano
carcinomas
epithelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96942362T
Other languages
English (en)
Spanish (es)
Inventor
Karl-Heinz Heider
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Karlsruher Institut für Technologie
Original Assignee
Boehringer Ingelheim International GmbH
Forschungszentrum Karlsruhe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim International GmbH, Forschungszentrum Karlsruhe GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2190484T3 publication Critical patent/ES2190484T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES96942362T 1995-12-06 1996-12-05 Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano. Expired - Lifetime ES2190484T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17

Publications (1)

Publication Number Publication Date
ES2190484T3 true ES2190484T3 (es) 2003-08-01

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96942362T Expired - Lifetime ES2190484T3 (es) 1995-12-06 1996-12-05 Procedimiento para el diagnostico y la terapia de carcinomas del epitelio plano.

Country Status (25)

Country Link
EP (1) EP0865609B1 (pl)
JP (1) JP2000502067A (pl)
KR (1) KR100473824B1 (pl)
CN (1) CN1151377C (pl)
AR (1) AR004360A1 (pl)
AT (1) ATE235056T1 (pl)
AU (1) AU726704B2 (pl)
BG (1) BG62985B1 (pl)
BR (1) BR9611901A (pl)
CA (1) CA2239709A1 (pl)
CO (1) CO4520233A1 (pl)
CZ (1) CZ174198A3 (pl)
DE (1) DE59610248D1 (pl)
DK (1) DK0865609T3 (pl)
EE (1) EE03783B1 (pl)
ES (1) ES2190484T3 (pl)
MX (1) MX9804459A (pl)
NO (1) NO319903B1 (pl)
NZ (1) NZ324314A (pl)
PL (1) PL184521B1 (pl)
PT (1) PT865609E (pl)
SK (1) SK284378B6 (pl)
TR (1) TR199801027T2 (pl)
UY (1) UY24389A1 (pl)
WO (1) WO1997021104A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EA200301169A1 (ru) * 2001-05-18 2004-06-24 Бёрингер Ингельхайм Интернациональ Гмбх АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ CD44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
SI2531527T1 (sl) * 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
KR20210004961A (ko) * 2018-02-22 2021-01-13 아브마트 상하이 컴퍼니, 엘티디. 치료 항체 및 그의 용도
EP4532019A2 (en) 2022-05-25 2025-04-09 Akiram Therapeutics AB Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2165461A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen Compositions and diagnostic methods using monoclonal antibodies against cd44v6
CA2164728A1 (en) * 1993-06-22 1995-01-05 Helmut Ponta Processes for diagnosing and analysing tumours
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
HK1011560A1 (en) 1999-07-16
BG102513A (en) 1999-02-26
KR100473824B1 (ko) 2005-09-30
EP0865609A1 (de) 1998-09-23
TR199801027T2 (xx) 1998-10-21
CZ174198A3 (cs) 1999-02-17
JP2000502067A (ja) 2000-02-22
EP0865609B1 (de) 2003-03-19
CA2239709A1 (en) 1997-06-12
SK73698A3 (en) 1999-01-11
SK284378B6 (sk) 2005-02-04
EE9800164A (et) 1998-12-15
CN1207811A (zh) 1999-02-10
AU1177397A (en) 1997-06-27
DK0865609T3 (da) 2003-06-23
EE03783B1 (et) 2002-06-17
NZ324314A (en) 2000-02-28
AU726704B2 (en) 2000-11-16
KR19990071952A (ko) 1999-09-27
AR004360A1 (es) 1998-11-04
CO4520233A1 (es) 1997-10-15
PL327066A1 (en) 1998-11-23
NO319903B1 (no) 2005-09-26
PL184521B1 (pl) 2002-11-29
BG62985B1 (bg) 2000-12-29
UY24389A1 (es) 2001-10-25
ATE235056T1 (de) 2003-04-15
NO982588L (no) 1998-08-05
DE59610248D1 (de) 2003-04-24
MX9804459A (es) 1998-09-30
NO982588D0 (no) 1998-06-05
CN1151377C (zh) 2004-05-26
WO1997021104A1 (de) 1997-06-12
BR9611901A (pt) 1999-03-02
PT865609E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
AU563356B2 (en) Conjugate of enzyme and antibody
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
PE20050712A1 (es) Anticuerpos rg1
ES2182906T3 (es) Grapa quirurgica helicoidal.
ES2151603T3 (es) Anticuerpo monoclonal contra cd44v6.
CY1117764T1 (el) Χιμαιρικα υβριδια μονομερους-διμερους ανοσοσφαιρινης
SE7512192L (sv) Cancerantigen, cancerterapi och cancerdiagnostikum
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
MXPA01003344A (es) Composiciones y metodos para inmunoterapia especifica de wt1.
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
MY154009A (en) Anti-alpha v beta 6 antibodies
ATE424560T1 (de) Marker für neuromyelitis optica
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
DE69729307D1 (de) Cyanidinzusammensetzungen und deren therapeutische und diagnostische verwendungen
NO965395L (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
AR004360A1 (es) Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas.
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
CO4940435A1 (es) Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6- (ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol o un solvato del mismo
DK1173766T3 (da) Isoform af tenascin-C som markör for neoplasier